Sanofi (SNY)
| Market Cap | 119.20B |
| Revenue (ttm) | 54.03B |
| Net Income (ttm) | 5.03B |
| Shares Out | 1.25B |
| EPS (ttm) | 4.00 |
| PE Ratio | 23.72 |
| Forward PE | 11.22 |
| Dividend | $2.04 (4.27%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 2,373,375 |
| Open | 46.92 |
| Previous Close | 47.50 |
| Day's Range | 46.89 - 47.90 |
| 52-Week Range | 45.22 - 58.97 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 57.50 (+20.52%) |
| Earnings Date | Jan 30, 2025 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric ... [Read more]
Financial Performance
In 2023, Sanofi's revenue was 46.03 billion, an increase of 1.42% compared to the previous year's 45.39 billion. Earnings were 5.40 billion, a decrease of -35.49%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $57.5, which is an increase of 20.52% from the latest price.
News
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replac...
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and C...
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
BrightInsight announced an expanded global digital partnership with Sanofi to build branded patient apps to drive adoption, adherence, and persistence.
Teva, Sanofi say drug to treat IBD met primary targets
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease
Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn's disease Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most co...
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-r...
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US First non-mRNA combination vaccine candidates that include two already licensed vac...
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained MR...
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
HOUSTON & SEATTLE--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of canc...
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024. Following the press release on October 21, 2024 and the plan to transfer a 50% controllin...
Global Fortune 500 Company Doubles Down on Beijing E-Town with Back-to-Back Investments Over Three Years: Insights from the Sanofi Project into E-Town's Business Environment
BEIJING, Dec. 05, 2024 (GLOBE NEWSWIRE) -- On December 2nd, the Administrative Committee of the Beijing Economic-Technological Development Area (Beijing E-Town) and the Sanofi Group signed a memorandu...
China's First International Pharma Biotherapeutic API Project Launched in Beijing E-Town -- Sanofi Invests Approximately 1 Billion Euros in New Insulin Production Facility
BEIJING, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The global pharmaceutical giant Sanofi has once again boosted its investment in Beijing E-Town. On December 2nd, the Administrative Committee of the Beijing ...
Sanofi to Invest $1 Billion in New Insulin Manufacturing Base in China
The new base, which will be located in Yizhuang, Beijing, marks Sanofi's second production site in the capital and its fourth in the country.
Sanofi to invest $1 bln in insulin production site in Beijing, local authority says
French drugmaker Sanofi plans to invest 1 billion euros ($1.05 billion) to build a new insulin production base in Beijing, a local authority in the city said on Monday, citing a memorandum of understa...
Pharma giant Sanofi opens $595 million vaccine facility in Singapore to boost preparedness for potential pandemics
The facility, known as Modulus, can switch between making different vaccines or treatments in a matter of days. It will contribute about 200 skilled jobs to Singapore, and will be fully operational by...
Sanofi plans to change hospital drug-discount program, WSJ reports
French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income and uninsured patients, the Wall Street Journal reported on Friday.
Recordati CEO sees 'substantial opportunity' in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More...
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in combination with ...
Healx announces agreement with Sanofi to seek new rare disease indications for compound using AI drug discovery platform
CAMBRIDGE, England--(BUSINESS WIRE)--Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indicatio...